Wells Fargo’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $132K | Sell |
10,445
-20,271
| -66% | -$272K | ﹤0.01% | 4946 |
|
|
2025
Q4 | $484K | Buy |
30,716
+15,117
| +97% | +$192K | ﹤0.01% | 4521 |
|
|
2025
Q3 | $187K | Buy |
15,599
+521
| +3% | +$4.16K | ﹤0.01% | 4969 |
|
|
2025
Q2 | $114K | Buy |
15,078
+879
| +6% | +$5.29K | ﹤0.01% | 5114 |
|
|
2025
Q1 | $78.4K | Sell |
14,199
-1,682
| -11% | -$10.4K | ﹤0.01% | 5223 |
|
|
2024
Q4 | $91.3K | Buy |
15,881
+6,518
| +70% | +$62.5K | ﹤0.01% | 5248 |
|
|
2024
Q3 | $97K | Buy |
9,363
+395
| +4% | +$5.17K | ﹤0.01% | 5040 |
|
|
2024
Q2 | $116K | Sell |
8,968
-15,941
| -64% | -$215K | ﹤0.01% | 4843 |
|
|
2024
Q1 | $435K | Buy |
24,909
+18,731
| +303% | +$248K | ﹤0.01% | 3982 |
|
|
2023
Q4 | $58.1K | Buy |
6,178
+1,200
| +24% | +$11.2K | ﹤0.01% | 5212 |
|
|
2023
Q3 | $55.6K | Sell |
4,978
-19,505
| -80% | -$314K | ﹤0.01% | 5125 |
|
|
2023
Q2 | $524K | Buy |
24,483
+10,531
| +75% | +$310K | ﹤0.01% | 3910 |
|
|
2023
Q1 | $564K | Buy |
13,952
+13,136
| +1,610% | +$627K | ﹤0.01% | 3754 |
|
|
2022
Q4 | $38K | Sell |
816
-1,045
| -56% | -$47.6K | ﹤0.01% | 4990 |
|
|
2022
Q3 | $96K | Sell |
1,861
-219
| -11% | -$12.8K | ﹤0.01% | 4619 |
|
|
2022
Q2 | $98K | Sell |
2,080
-14,604
| -88% | -$793K | ﹤0.01% | 4645 |
|
|
2022
Q1 | $1.19M | Sell |
16,684
-5,659
| -25% | -$368K | ﹤0.01% | 3740 |
|
|
2021
Q4 | $1.67M | Buy |
22,343
+6,835
| +44% | +$536K | ﹤0.01% | 3669 |
|
|
2021
Q3 | $881K | Sell |
15,508
-5,157
| -25% | -$255K | ﹤0.01% | 4329 |
|
|
2021
Q2 | $910K | Buy |
20,665
+16,468
| +392% | +$806K | ﹤0.01% | 4269 |
|
|
2021
Q1 | $207K | Sell |
4,197
-38,047
| -90% | -$1.9M | ﹤0.01% | 5132 |
|
|
2020
Q4 | $1.78M | Buy |
42,244
+1,669
| +4% | +$73.4K | ﹤0.01% | 3583 |
|
|
2020
Q3 | $1.86M | Sell |
40,575
-918
| -2% | -$44.5K | ﹤0.01% | 3360 |
|
|
2020
Q2 | $2.08M | Buy |
41,493
+7,142
| +21% | +$370K | ﹤0.01% | 3232 |
|
|
2020
Q1 | $1.77M | Buy |
34,351
+2,257
| +7% | +$120K | ﹤0.01% | 3111 |
|
|
2019
Q4 | $1.98M | Buy |
32,094
+2,148
| +7% | +$133K | ﹤0.01% | 3355 |
|
|
2019
Q3 | $1.8M | Buy |
29,946
+1,120
| +4% | +$83.2K | ﹤0.01% | 3420 |
|
|
2019
Q2 | $2.43M | Buy |
28,826
+1,668
| +6% | +$150K | ﹤0.01% | 3172 |
|
|
2019
Q1 | $2.6M | Sell |
27,158
-426
| -2% | -$38.2K | ﹤0.01% | 3136 |
|
|
2018
Q4 | $1.95M | Buy |
27,584
+3,529
| +15% | +$271K | ﹤0.01% | 3279 |
|
|
2018
Q3 | $2.06M | Sell |
24,055
-18,716
| -44% | -$1.87M | ﹤0.01% | 3381 |
|
|
2018
Q2 | $4.96M | Buy |
42,771
+17,465
| +69% | +$1.74M | ﹤0.01% | 2696 |
|
|
2018
Q1 | $2.05M | Buy |
25,306
+1,918
| +8% | +$148K | ﹤0.01% | 3364 |
|
|
2017
Q4 | $1.37M | Buy |
23,388
+5,191
| +29% | +$260K | ﹤0.01% | 3679 |
|
|
2017
Q3 | $852K | Buy |
18,197
+4,886
| +37% | +$196K | ﹤0.01% | 3958 |
|
|
2017
Q2 | $479K | Sell |
13,311
-8,083
| -38% | -$259K | ﹤0.01% | 4243 |
|
|
2017
Q1 | $660K | Buy |
21,394
+9,674
| +83% | +$301K | ﹤0.01% | 4059 |
|
|
2016
Q4 | $393K | Buy |
11,720
+5,265
| +82% | +$151K | ﹤0.01% | 4365 |
|
|
2016
Q3 | $172K | Sell |
6,455
-73,692
| -92% | -$1.71M | ﹤0.01% | 4564 |
|
|
2016
Q2 | $1.77M | Sell |
80,147
-1,003
| -1% | -$26.3K | ﹤0.01% | 3056 |
|
|
2016
Q1 | $2.38M | Sell |
81,150
-8,391
| -9% | -$234K | ﹤0.01% | 2798 |
|
|
2015
Q4 | $2.96M | Buy |
89,541
+52,600
| +142% | +$1.71M | ﹤0.01% | 2699 |
|
|
2015
Q3 | $1.33M | Buy |
36,941
+1,755
| +5% | +$75.4K | ﹤0.01% | 3296 |
|
|
2015
Q2 | $1.58M | Buy |
35,186
+963
| +3% | +$37.5K | ﹤0.01% | 3245 |
|
|
2015
Q1 | $1.05M | Sell |
34,223
-16,501
| -33% | -$642K | ﹤0.01% | 3508 |
|
|
2014
Q4 | $2.58M | Buy |
50,724
+24,748
| +95% | +$1.11M | ﹤0.01% | 2823 |
|
|
2014
Q3 | $1.03M | Sell |
25,976
-683
| -3% | -$27.2K | ﹤0.01% | 3446 |
|
|
2014
Q2 | $1.15M | Sell |
26,659
-27,248
| -51% | -$1.04M | ﹤0.01% | 3424 |
|
|
2014
Q1 | $2.16M | Buy |
53,907
+22,513
| +72% | +$818K | ﹤0.01% | 2956 |
|
|
2013
Q4 | $857K | Buy |
31,394
+14,026
| +81% | +$340K | ﹤0.01% | 3510 |
|
|
2013
Q3 | $398K | Buy |
+17,368
| New | +$332K | ﹤0.01% | 3866 |
|
Other funds holding ENTA
FCM
KAM
DTC
VCM
VPM
SSC
Wells Fargo's ENTA Position: Q1 2026 in Review
Wells Fargo reduced its Enanta Pharmaceuticals (ENTA) stake by 66% in Q1 2026, selling an estimated $272K and leaving 10,445 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #4946.
Wells Fargo first reported a position in ENTA in Q3 2013 and has held it in 51 quarters since. The position peaked at $4.96M in Q2 2018. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.
- Wells Fargo held 10,445 shares of Enanta Pharmaceuticals worth $132K as of Q1 2026.
- Wells Fargo sold 20,271 Enanta Pharmaceuticals shares in Q1 2026, an estimated $272K.
- Enanta Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4946 holding.
- Wells Fargo first reported a position in Enanta Pharmaceuticals in Q3 2013 and has held it in 51 quarters since.
- Wells Fargo's Enanta Pharmaceuticals position peaked at $4.96M in Q2 2018.
- 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.
Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.